Jeffrey L. Wade - Feb 28, 2023 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role
President and CFO
Signature
/s/ Jeffrey L. Wade
Stock symbol
LXRX
Transactions as of
Feb 28, 2023
Transactions value $
-$65,653
Form type
4
Date filed
3/1/2023, 03:48 PM
Previous filing
Feb 13, 2023
Next filing
Jun 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXRX Common Stock Options Exercise +30.5K +15.73% 224K Feb 28, 2023 Direct F1
transaction LXRX Common Stock Options Exercise +11.2K +4.99% 235K Feb 28, 2023 Direct F1
transaction LXRX Common Stock Options Exercise +37.3K +15.84% 273K Feb 28, 2023 Direct F1
transaction LXRX Common Stock Tax liability -$65.7K -30.3K -11.1% $2.17 242K Feb 28, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXRX Restricted Stock Units Options Exercise -30.5K -100% 0 Feb 28, 2023 Common Stock 30.5K Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -11.2K -50% 11.2K Feb 28, 2023 Common Stock 11.2K Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -37.3K -33.33% 74.5K Feb 28, 2023 Common Stock 37.3K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock.
F2 Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3 Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.